<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">915</article-id><article-id pub-id-type="doi">10.36691/RJA915</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Specific subcutaneus immunotherapy by a birch extract absorbed onto calcium phosphate</article-title><trans-title-group xml:lang="ru"><trans-title>Аллергенспецифическая иммунотерапия аллергенным экстрактом пыльцы деревьев, адсорбированным на суспензии кальция фосфата</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Mokronosova</surname><given-names>M A</given-names></name><name xml:lang="ru"><surname>Мокроносова</surname><given-names>М А</given-names></name></name-alternatives><bio xml:lang="en"><p>Mechnikov's Research Institute for vaccines and sera</p></bio><bio xml:lang="ru"><p>ГУ НИИ вакцин и сывороток им. И.И. Мечникова</p></bio><email>mmokronosova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Korovkina</surname><given-names>E S</given-names></name><name xml:lang="ru"><surname>Коровкина</surname><given-names>Е С</given-names></name></name-alternatives><bio xml:lang="en"><p>Mechnikov's Research Institute for vaccines and sera</p></bio><bio xml:lang="ru"><p>ГУ НИИ вакцин и сывороток им. И.И. Мечникова</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Mechnikov's Research Institute for vaccines and sera</institution></aff><aff><institution xml:lang="ru">ГУ НИИ вакцин и сывороток им. И.И. Мечникова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2010-08-15" publication-format="electronic"><day>15</day><month>08</month><year>2010</year></pub-date><volume>7</volume><issue>4</issue><issue-title xml:lang="en">NO04 (2010)</issue-title><issue-title xml:lang="ru">№4 (2010)</issue-title><fpage>79</fpage><lpage>84</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2009, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2009, Фармарус Принт Медиа</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2011-12-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/915">https://rusalljournal.ru/raj/article/view/915</self-uri><abstract xml:lang="en"><p>Background. Allergic rhinitis is a common disease, affecting 25-35% of the population. Birch pollen is a significant cause of immediate
hypersensitivity among sensitive subjects, affecting about 80% of the population in the central part of Russian Federation. Specific
subcutaneus immunotherapy (SCIT) is the only treatment producing lasting clinical improvement in patients with allergy.
The aim, of the study was to investigate the efficacy of one - year SCIT for allergic rhinoconjunctivitis for birch pollen using the
Average Rhinoconjunctivitis Total Symptom Score (ARTSS) and Average Rescue Medication Score (ARMS).
Materials and methods. 54 subjects with IgE-mediated seasonal allergic rhinoconjunctivitis with/without seasonal asthma were
enrolled; 47 patients with pollen allergy were included in a control group. All patients were sensitized to birch pollen-allergens.
SCIT was performed during 9 months 2009-2010 years by a birch extract standardized in IR and absorbed onto calcium phosphate
(Phostal, France). Patients were asked to complete diary during the birch pollination season (from 1 April to 1 June). Pollen grains
were counted daily during the pollen seasons by standardized protocol and the amount of pollen was expressed as the number of
pollen grains/m3 air. The ARTSS was derived from individual symptom scores for nasal and eye symptoms during the pollen season.
In addition there was a daily score for the use of rescue medication (ARMS). Rescue medication allowed included Hl-antihistamines,
nasal steroids, oral steroids; each puff, drop (nostril/eye), tablet counted as one point.
Results. The seasonal pollen counts and the duration of the pollen season had differed in 2009 and in 2010. Reduction in ARTSS of
29% and decrease in ARMS of 28,9% were found in the birch pollen season for subjects treated with the SCIT compared with controls
after one year of treatment. The immunotherapy after the end of the treatment was not effective in 3 patients (5%).
Conclusion. Immunotherapy by Phostal shows clinical effect on development of seasonal rhinoconjunctivitis. The decrease in ARTSS
for Phostal-treated patients that occurred in parallel with a marked reduction in their requirement for ARMS provides additional
evidence for the efficacy of SCIT over and above usual pharmacotherapy for rhinitis.</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования. Оценить клинический эффект терапии препаратом Фосталь (аллергенный экстракт пыльцы деревьев, адсорбированный на суспензии кальция фосфата, для подкожного введения) у пациентов с аллергическим интермиттируюгцим риноконъюнктивитом (АИРК), сенсибилизированных к пыльце деревьев, в открытом рандомизированном исследовании.
В основной группе исследования принимали участие 54 пациента с диагнозом АИРК, получавшие препарат Фосталь (ПФ). Группу сравнения составили 47 пациентов АИРК, которые не получали АСИТ. У всех пациентов выявляли положительные результаты кожного тестирования с аллергенами пыльцы деревьев (береза, ольха, легцина, дуб) с образованием папулы диаметром более 5 мм. Присутствие аллергенспецифических IgE к пыльце березы в сыворотке крови определяли при помощи использования метода ImmunoCap-100 (Phadia AB, Sweden). Тяжесть течения АИРК оценивали в соответствии со стандартными схемами: шкалой учета симптомов АИРК {Average Rhino conjunctivitis Total Symptom. Score) и шкалой учета использования медикаментов {Average Rescue Medication Score).
Результаты. В ходе АСИТ не наблюдалось системных аллергических реакций на введение ПФ. Местные реакции отмечались с дозы аллергена 0,4 мл 0,1 ИР/мл. После завершения 1-го курса лечения отмечается снижение потребности в использовании медикаментов (ARMS) на 28,9%, а также снижение среднего балла учета симптомов АИРК (ARTSS) на 29%.
Заключение. АСИТ, проводимая ПФ, может быть рекомендована для использования в практике врачей-аллергологов для лечения пациентов, сенсибилизированных к пыльце деревьев.</p></trans-abstract><kwd-group xml:lang="en"><kwd>specific subcutaneous immunotherapy</kwd><kwd>allergic rhinoconjunctivitis</kwd><kwd>birch extract absorbed onto calcium phosphate</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аллергенспецифическая подкожная иммунотерапия</kwd><kwd>аллергический интермиттирующий риноконъюнктивит</kwd><kwd>аллергенный экстракт пыльцы деревьев</kwd><kwd>адсорбированный на суспензии кальция фосфата</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Stewart M., Ferguson В., Fromer L. Epidemiology and burden of nasal congestion. Int. J. Gen. Med. 2010, No. 3, p. 37-45.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Аллергический ринит и его влияние на астму Рос.Аллергол. Журн. 2010, № 1, с. 74-87.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Ильина Н.И. Классификация и эпидемиология аллергического ринита. Materia Medica. 1999, № 3, с. 3-10.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Eseverri J.L., Cozzo M., Marin A.M., Botey J. Epidemiology and chronology of allergic diseases and their risk factors. AUergol. Immunopathol (Madr). 1998, v. 26 (3), p. 90-97.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Freeman J., Noon L. Further observation on the treatment of hayfever by hypodermic inoculations of pollen vaccine. Lancet. 1911, v. 2, p. 81.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bousquet J., Lockey R., Mailing H.-J. (eds). WHO position paper. Allergen immunotherapy, therapeutic vaccines for allergic diseases. Allergy. 1998, v. 53, suppl. 44, p. 1-42.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Wallner M., Briza P., Thalhamer J., Ferreira F. Specific immunotherapy in pollen allergy. Curr. Opin. Mol. Ther. 2007, v. 9 (2), p. 160-167.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Calderon M., Mosges R., Helmich M., Demoly P. Towards evidence - based in specific grass pollen immunotherapy. Allergy. 2010, v. 65, p. 420-434.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Курбачева О.М., Павлова К.С., Ильина Н.И. и соавт. Эффективность проведения аллерген-специфической иммунотерапии препаратом Фосталь у больных поллинозом. Рос. Аллергол. Журн. 2009, № 3, с. 58-64.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Canonica G.W., Baena-Cagnani C.E., Bousquet J. et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A Statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007, v. 62, p. 317-324.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Clark J., Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy. 2007, v. 62, p. 1023-1028</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Valenta R., Lidholm J., Niederberger V. et al. The recombinant allergen - based concept of component - resolved diagnostics and immunotherapy (CRD and CRT). Clin. Exp. Allergy. 1999, v. 29, p. 896-904.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Corrigan C.J., Kettner J., Doemer C. et al. Efficacy and safety of preseasonal - specific immunotherapy with an aluminium-absorbed six-grass pollen allergoid. Allergy, 2005, v. 60, p. 801-802.</mixed-citation></ref></ref-list></back></article>
